Play Earnings CallPlay Earnings Call
Jade Biosciences, Inc. (JBIO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 2:15 PM EST
Company Participants
Tom Frohlich – CEO & Director
Andrew King – Chief Scientific Officer & Head of R&D
Conference Call Participants
Cliff Zhang
Presentation
Cliff Zhang
Good morning, everyone. I hope everyone’s had a good conference week. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Cliff Zhang, a member of the Healthcare Investment Banking team based in New York. Our next presenting company is Jade Biosciences. And speaking on behalf of the company, I’m pleased to welcome CEO, Tom Frohlich. Please give it up for Tom.
Tom Frohlich
CEO & Director
Thanks, Cliff. It really — it’s a pleasure to be here. Thanks for hosting us at the conference. I’m really pleased to provide an overview of Jade on behalf of the team. Very exciting time for us as the company. So pleased to provide an overview. I will be making forward-looking statements. So if you have more request for information, please contact or please read our SEC filings. So Jade Biosciences, we’re a company that is really dedicated to developing best-in-class therapeutics for autoimmune disease. We were launched in the middle of 2024, really based on 3 assets that we have access to from a company that we’ve licensed to and have access to another one from Paragon Therapeutics.
Many of you are probably familiar with Paragon. They’re a protein engineering company based out of Boston, have an excellent track record of developing very high-quality monoclonal antibodies, have a particular expertise in developing high-affinity binding antibodies, but also in half-life extension technology. So really, the playbook for our 3 assets is to have best-in-class possibilities to go after targets that have a high degree of clinical validation, but where we do believe we can improve upon
